Antiarrhythmic Effect of Ranolazine in Combination with Class <scp>III</scp> Drugs in an Experimental Whole‐Heart Model of Atrial Fibrillation

Abstract

In this study, ranolazine on top of class III antiarrhythmic therapy had a beneficial effect. The increase in interatrial conduction time and marked atrial aPRR suppressed AF. These results shed further light on a potential therapeutic benefit of ranolazine on top of conventional antiarrhythmic therapy for rhythm control in AF.